PROKIDNEY CORP.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
PROK$1.11-3.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share data)
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| (Unaudited) | ||
| Assets | ||
| Cash and cash equivalents | $95,323 | $99,120 |
| Marketable securities | 176,402 | 259,172 |
| Interest receivable | 1,237 | 2,447 |
| Prepaid assets | 3,516 | 4,192 |
| Prepaid clinical | 4,351 | 11,505 |
| Assets held for sale | 19,050 | 19,368 |
| Other current assets | 110 | 80 |
| Total current assets | 299,989 | 395,884 |
| Fixed assets, net | 47,754 | 42,222 |
| Right of use assets, net | 3,865 | 2,967 |
| Total assets | $351,608 | $441,073 |
| Liabilities and Stockholders' Deficit | ||
| Accounts payable | $1,942 | $3,633 |
| Lease liabilities | 991 | 765 |
| Accrued expenses and other | 26,068 | 31,137 |
| Income taxes payable | 62 | 682 |
| Total current liabilities | 29,063 | 36,217 |
| Income tax payable, net of current portion | 962 | 748 |
| Lease liabilities, net of current portion | 3,245 | 2,471 |
| Total liabilities | 33,270 | 39,436 |
| Commitments and contingencies | ||
| Redeemable noncontrolling interest | 1,326,358 | 1,396,591 |
| Stockholders’ deficit | ||
| Class A common stock, $0.0001 par value; 700,000,000 and 500,000,000 shares authorized as of September 30, 2025 and December 31, 2024, respectively; 135,977,945 and 128,054,417 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 14 | 13 |
| Class B common stock, $0.0001 par value; 500,000,000 shares authorized; 159,288,931 and 163,693,707 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 16 | 16 |
| Additional paid-in capital | 242,480 | 205,736 |
| Accumulated other comprehensive gain | 74 | 130 |
| Accumulated deficit | (1,250,604) | (1,200,849) |
| Total stockholders' deficit | (1,008,020) | (994,954) |
| Total liabilities and stockholders' deficit | $351,608 | $441,073 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.